Current issues in adjuvant treatment of stage II colon cancer

Annals of Surgical Oncology

Volumn 13, Issue 6, 2006, Pages 887-898

  André, Thierry ^a,b,c   Sargent, Daniel ^d   Tabernero, Josep ^e   O'Connell, Michael ^f   Buyse, Marc ^g   Sobrero, Alberto ^h   Misset, Jean Louis ⁱ   Boni, Corrado ^j   De Gramont, Aimery ^b,c  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c GERCOR (Franch Oncology Research Group)   (France)

^d MAYO CLINIC   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f NSABP Foundation Inc   (United States)

^g INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j S MARIA NUOVA HOSPITAL   (Italy)

more..

Author keywords

5 Fluorouracil; Adjuvant chemotherapy; Colon cancer, stage II; Leucovorin; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; MOLECULAR MARKER; OXALIPLATIN; UFT;

ALLELE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; LYMPH NODE; MEDICAL DECISION MAKING; META ANALYSIS; MICROSATELLITE INSTABILITY; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR PERFORATION;

ALLELIC IMBALANCE; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; MICROSATELLITE REPEATS; NEOPLASM STAGING; PROGNOSIS;

EID: 33646589659     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.07.003     Document Type: Review

References (62)

1. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
2. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893-900.
3. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47.
4. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
5. Tournigand C, André T, Louvet C, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
6. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 2002; 21:129a.
7. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
10. Datamonitor. Treatment Algorithms: Colorectal Cancer 5th Edition - New Gold Standards Emerge but Unmet Need Remains. 2003. Available at: http://www.datamonitor.com/~5316ab639141457fble7238dae8507c9~/industries/ research/?pid=DMHC1816&type=Report. Accessed: June 21, 2005.
11. Van Cutsem E, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002; 38:1429-36.
12. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739-57.
13. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28(Suppl 1):20-4.
14. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant chemotherapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8.
15. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-44.
16. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
17. Haller DG, Catalano PJ, MacDonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year report of INT-0089 (abstract 982). Prof Am Soc Clin Oncol 1998; 17:256a.
18. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553-9.
19. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 2004; 350:2343-51.
20. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C07 (abstract 3500). J Clin Oncol 2005; 23(16 Suppl; Pt 2 of 2):1092s.
21. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349-55.
22. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. Clin Oncol 1999; 17:1356-63.
23. Liver Infusion Meta-Analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 89:497-505.
24. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-806.
25. Adjuvant systemic therapy tools. Available at: http://www.mayoclinic.com/ calcs. Accessed: June 21, 2005.
26. Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1:379-92.
27. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004; 22:3395-407.
28. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484-92.
29. Taal BG, Van Tinteren H, Zoetmulder FAN, et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85:1437-43.
30. Gray RG, Barnwell J, Hills R, et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients (abstract 3501). Proc Am Soc Clin Oncol 2004; 23:246.
31. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20:3999-4005.
32. Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial (abstract 3509). J Clin Oncol 2004; 22(14 Suppl):315s.
33. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06 (abstract 3508). J Clin Oncol 2004; 22(14 Suppl):315s.
34. Hickish T, Boni C, Navarro M, et al. Stage II patients in the "MOSAIC" trial evaluating oxaliplatin/5-FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis (abstract 284P). Ann Oncol 2004; 15 (Suppl 3):iii76.
35. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091-7.
36. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51:65-9.
37. Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92:1435-43.
38. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002.
39. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-5.
40. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089. J Clin Oncol 2003; 21:2912-9.
41. Bukholm IR, Bondi J, Wiik P, et al. Presence of isolated tumor cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol 2003; 29:862-6.
42. Fielding LP, Arsenault PA, Chaphuis PH, et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6:325-44.
43. Maurel J, Launoy G, Grosclaude P, et al. Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer 1998; 82:1482-6.
44. Goldstein NS, Weldon S, Coffey M, Layfield LJ. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma: trends over time and a recommendation for a minimum number of lymph nodes to be removed. Am J Clin Pathol 1996; 106:209-16.
45. Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17:2896-900.
46. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-19.
47. Zaniboni A, Labianca R, for the Gruppo Italiano per lo Studio e la Cura dei Tumori del Digerente. Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 2004; 15:1310-8.
48. Saha S, Dan AG, Beutler T, et al. Sentinel lymph node mapping technique in colon cancer. Semin Oncol 2004; 31:374-81.
49. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-9.
50. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91:1295-303.
51. Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53:371-5.
52. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-31.
53. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.
54. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126:394-401.
55. Allegra CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med 2003; 349:1774-6.
56. Lanza G, Matteuzzi M, Gafá R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79:390-5.
57. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-206.
58. Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002; 359:219-25.
59. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9:4116-24.
60. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529-36.
61. Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2004; 22:1572-82.
62. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-71.